|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | (-)-Nutlin-3 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||
| 化学式 | C30H30Cl2N4O4 |
||||||||||
| 分子量 | 581.49 | CAS No. | 675576-98-4 | ||||||||
| Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (171.97 mM) | ||||||||
| Ethanol | 100 mg/mL (171.97 mM) | ||||||||||
| Water | Insoluble | ||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||
| 製品説明 | Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. |
|---|---|
| in vitro | Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM of this compound led to >90% inhibition of NIH3T3 cells’ growth[1]. This compound stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. It effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. This chemical induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1]. |
| in vivo | Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. This compound is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with this chemical. |
| 特徴 | Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53. |
| キナーゼアッセイ | Biacore studies | |
|---|---|---|
| Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of this compound is calculated as a percentage of binding in the absence of this compound and IC50 is calculated using Microsoft Excel | ||
| 細胞アッセイ | 細胞株 | OSA, T778, RMS13, U2OS, SaOS-2 |
| 濃度 | ~5 μM | |
| 反応時間 | 120 h | |
| 実験の流れ | SRB | |
| 動物実験 | 動物モデル | SJSA-1 xenograft |
| 投薬量 | 50, 100, 200 mg/kg twice daily | |
| 投与方法 | oral | |
|

, , J Cell Mol Med, 2017, 21(12):3435-3444

Data from [Data independently produced by , , Oncogene, 2016, 35(42):5552-5564]

Data from [Data independently produced by , , Int J Cancer. 2019, 144(4):777-787]
| Combined MEK and PARP inhibition enhances radiation response in rectal cancer [ Cell Rep Med, 2025, 6(8):102284] | PubMed: 40782795 |
| Chaperone-mediated autophagy directs a dual mechanism to balance premature senescence and senolysis to prevent intervertebral disc degeneration [ Bone Res, 2025, 13(1):62] | PubMed: 40506462 |
| WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer [ EMBO J, 2025, 10.1038/s44318-025-00495-0] | PubMed: 40551011 |
| Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy [ J Exp Clin Cancer Res, 2025, 44(1):128] | PubMed: 40275403 |
| The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136] | PubMed: 40163352 |
| Identification of CNOT1-CCR4-NOT as a suppressor of 53BP1-p53-p21 signaling [ Cell Rep, 2025, 44(8):116090] | PubMed: 40742806 |
| The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein [ Cell Mol Life Sci, 2025, 82(1):233] | PubMed: 40512405 |
| Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway [ Cell Death Discov, 2025, 11(1):416] | PubMed: 40883295 |
| CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation [ Mol Oncol, 2025, 10.1002/1878-0261.70143] | PubMed: 41105927 |
| Ferroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma [ Oncol Lett, 2025, 29(6):269] | PubMed: 40247991 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。